Spacecraft

Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic

Retrieved on: 
Wednesday, February 7, 2024

Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.
  • In this role, Dr. Rock will be responsible for guiding the company’s scientific strategy and leading efforts to advance Cartography’s internal programs into the clinic.
  • “As Cartography moves into the next phase of development focused on advancing our internal pipeline discovered from our Atlas platform, we are thrilled to welcome Dan to the team.
  • “I’m honored to be joining a team at the forefront of innovation and I look forward to leading the team as Chief Scientific Officer in the pursuit of better treatment options for patients with cancer.”

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
Wednesday, February 7, 2024

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 6, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
  • Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.
  • Archived replays will be available for at least 30 days after the event.

Smart Lander for Investigating Moon “SLIM” Achieves World’s First High-Precision Landing on the Moon

Retrieved on: 
Tuesday, February 6, 2024

Mitsubishi Electric Corporation (TOKYO:6503) announced today that the Smart Lander for Investigating Moon (SLIM), a spacecraft developed by the company under contract with the Japan Aerospace Exploration Agency (JAXA), successfully achieved a high-precision landing on the lunar surface at 00:20 a.m. (Japan Standard Time) on January 20.

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO:6503) announced today that the Smart Lander for Investigating Moon (SLIM), a spacecraft developed by the company under contract with the Japan Aerospace Exploration Agency (JAXA), successfully achieved a high-precision landing on the lunar surface at 00:20 a.m. (Japan Standard Time) on January 20.
  • High-precision landing technology for the precise positioning of spacecraft will become increasingly important for future lunar and planetary exploration.
  • Mitsubishi Electric was awarded a contract in 2015 with primary responsibility for the design, manufacture and testing of the SLIM at the company’s Kamakura Works in Kamakura, Kanagawa Prefecture, Japan.
  • In collaboration with JAXA, Mitsubishi Electric also developed the guidance, navigation and control (GNC) system used for high-precision landings.

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m.
  • ET.
  • A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com , and an archived replay will be available for approximately 90 days following the event.

Northrop Grumman’s 20th Cargo Resupply Mission Successfully Launches to the International Space Station for NASA

Retrieved on: 
Tuesday, January 30, 2024

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation’s (NYSE: NOC) Cygnus cargo delivery spacecraft was successfully launched to the International Space Station today by SpaceX’s Falcon 9 rocket from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.

Key Points: 
  • CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation’s (NYSE: NOC) Cygnus cargo delivery spacecraft was successfully launched to the International Space Station today by SpaceX’s Falcon 9 rocket from Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida.
  • Northrop Grumman’s Cygnus spacecraft for the NG-20 cargo delivery mission to the International Space Station launched from Cape Canaveral Space Force Station in Florida.
  • After its rendezvous with the International Space Station on February 1, Cygnus will remain attached to the station for up to six months.
  • Northrop Grumman’s Cygnus provides the only U.S. spacecraft reboost capability for the International Space Station.

Ascent Solar Begins Advocacy Outreach to Brief Private Sector Space Activities Interagency Steering Group Members on Advantages of Thin-Film Solar PV in Space

Retrieved on: 
Tuesday, January 30, 2024

The Group is tasked with creating an authorization and supervision framework for novel space activities.

Key Points: 
  • The Group is tasked with creating an authorization and supervision framework for novel space activities.
  • Within its mission statement , the framework states its intent to collaborate with members of the commercial space industry to advance national objectives.
  • These subsystems are a primary driver in conjunction event probabilities and consequence, two areas where Ascent’s thin-film technology can have major efficiency and cost benefits.
  • “Ascent is a leader in the proliferation of thin-film solar modules in space environments, and we look forward to detailing our industry expertise to the Group,” said Paul Warley, CEO of Ascent Solar Technologies.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, February 1, 2024

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

Carbice Collaborates with RTX’s Blue Canyon Technologies to Drive Deep Tech Innovation and Sustainability in Aerospace

Retrieved on: 
Wednesday, January 31, 2024

RTX’s Blue Canyon Technologies is a leading provider of turnkey small satellite solutions, including nanosatellites, microsatellites, and ESPA-class satellites.

Key Points: 
  • RTX’s Blue Canyon Technologies is a leading provider of turnkey small satellite solutions, including nanosatellites, microsatellites, and ESPA-class satellites.
  • Carbice Space Pad is a proven and reliable thermal solution that combines high-power dissipation performance with ease of use.
  • Carbice Space Pad negates this damage and delay by saving existing material from being discarded and avoiding an increased schedule risk.
  • Baratunde Cola and his team of pioneers have helped enable that speed and mission with Carbice Space Pad and Carbice SIM.

Norwegian Microsatellite Developed by Space Flight Laboratory (SFL) Achieves Optical Satellite-to-Ground Communications Link

Retrieved on: 
Wednesday, January 31, 2024

The NorSat-TD demonstration microsatellite developed by Space Flight Laboratory (SFL) for the Norwegian Space Agency (NOSA) has successfully transferred data to a ground station using optical communications technology.

Key Points: 
  • The NorSat-TD demonstration microsatellite developed by Space Flight Laboratory (SFL) for the Norwegian Space Agency (NOSA) has successfully transferred data to a ground station using optical communications technology.
  • The accomplishment is a first for a Dutch-built laser communication device and among the first achieved by a microsatellite.
  • View the full release here: https://www.businesswire.com/news/home/20240131013536/en/
    Artist rendering of NorSat-TD microsatellite developed by Space Flight Laboratory (SFL).
  • (Photo: Business Wire)
    Optical, or laser, communications between a satellite and ground station enable faster and more secure transmission of larger data sets than typically possible with radio communications.